Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8113833 | 0.89 | NR1H2 (0.46) | NR1H2HSD17B10HSD11B1ALDH1A1MEN1 | |
| SCHEMBL497157 | 0.89 | NR1H2 (0.46) | NR1H2HSD17B10HSD11B1ALDH1A1MEN1 | |
| SCHEMBL15184287 | 0.89 | NR1H2 (0.46) | NR1H2HSD17B10HSD11B1ALDH1A1MEN1 | |
| SCHEMBL4074539 | 0.84 | NR1H2 (0.43) | NR1H2HSD17B10HSD11B1CHRM2CHRM1 | |
| SCHEMBL2929834 | 0.84 | NR1H2 (0.43) | NR1H2HSD17B10HSD11B1CHRM2CHRM1 | |
| SCHEMBL2926494 | 0.84 | NR1H2 (0.43) | NR1H2HSD17B10HSD11B1CHRM2CHRM1 | |
| SCHEMBL3415478 | 0.84 | NR1H2 (0.43) | NR1H2HSD17B10HSD11B1CHRM2CHRM1 | |
| SCHEMBL1339459 | 0.84 | NR1H2 (0.43) | NR1H2HSD17B10HSD11B1CHRM2CHRM1 | |
| SCHEMBL3415474 | 0.84 | NR1H2 (0.43) | NR1H2HSD17B10HSD11B1CHRM2CHRM1 | |
| SCHEMBL4302765 | 0.80 | CHRM2 (0.41) | NR1H2HSD17B10CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106215-B2 | 3-aza-bicyclo[3.3.0]octane compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-31 | — | — | US | disclosed |
| US-8106215-B2 | 3-aza-bicyclo[3.3.0]octane compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-31 | — | — | US | disclosed |
| EP-2164847-B1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | HCRTR2, HCRTR1, OXTR | NR1H2 237/4885HSD17B10 2011/4885HSD11B1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.